person · Reporting owner
Horenshtein Hadar Mirit
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silexion Therapeutics CorpSLXN · Entity 8506 | CFO and Secretary | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silexion Therapeutics Corp
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 12,515 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 7,500 · Balance 12,515 F1: The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 50,146 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 5,015 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 50,146 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 5,015 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).
F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:05 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003134 · zk2635516.xml · nonDerivative · entry 1 Horenshtein Hadar Mirit · CIK 0002033245 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,515 F1 · security: The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 50,146 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 5,015 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). F2 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:16 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 49,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-000602 · ownership.xml · nonDerivative · entry 1 Horenshtein Hadar Mirit · CIK 0002033245 · CFO and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,146 F1 · security: The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively. F2 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's service as an officer of the Issuer. The grant was approved by the Issuer's board of directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.